HDEP-28

From WikiMD's WELLNESSPEDIA

HDEP-28 is a research chemical that belongs to the phenethylamine class of compounds. It is a derivative of methcathinone and is considered a stimulant and entactogen.

Chemistry[edit]

HDEP-28 is a phenethylamine derivative, specifically a methcathinone analog. It is structurally related to ethylone, a designer drug that is also a derivative of methcathinone. The chemical structure of HDEP-28 consists of a phenethylamine core, with an ethyl group attached to the alpha carbon, and a ketone group attached to the beta carbon. The phenyl ring is substituted at the 3 and 4 positions with a methylenedioxy group.

Pharmacology[edit]

The exact pharmacology of HDEP-28 is not well-studied. However, as a methcathinone derivative, it is likely to act as a norepinephrine-dopamine reuptake inhibitor (NDRI). This means it could potentially increase the levels of the neurotransmitters norepinephrine and dopamine in the brain by inhibiting their reuptake into neurons. This could result in stimulant and entactogenic effects.

Effects[edit]

The effects of HDEP-28 are not well-documented due to its status as a research chemical. However, anecdotal reports suggest that it may produce effects similar to other stimulants and entactogens, such as increased energy, euphoria, and enhanced sensory perception. These effects are thought to be due to its potential action as a norepinephrine-dopamine reuptake inhibitor.

Legal Status[edit]

The legal status of HDEP-28 varies by country. In some countries, it may be considered a controlled substance due to its structural similarity to other controlled substances, such as methcathinone and ethylone. In other countries, it may be legal to possess for research purposes.

See Also[edit]

References[edit]

This article is a stub related to chemistry. You can help WikiMD by expanding it!


HDEP-28[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.